Autologous bone marrow transplantation for acute lymphoblastic leukemia.

abstract：:Fifty-five patients with advanced multiple myeloma received purified CD34-selected peripheral blood progenitor cell transplants following myeloablative chemotherapy. A median of 4.1 x 10(6) CD34 cells/kg (range 1.2-30.7) were infused after busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg); granulocyte-macrophage co...

journal_title：Bone marrow transplantation

authors： Schiller G,Vescio R,Freytes C,Spitzer G,Lee M,Wu CH,Cao J,Lee JC,Lichtenstein A,Lill M,Berenson R,Berenson J

更新日期：1998-01-01 00:00:00

abstract：:In an effort to reduce the relapse rate after unpurged autologous bone marrow transplantation (ABMT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1), the standard conditioning regimens (cyclophosphamide/busulphan and cyclophosphamide/TBI) were intensified by adding idarubicin. Seventeen...

journal_title：Bone marrow transplantation

authors： Jerjis S,Roovers E,Muus P,Schaap N,de Witte T

更新日期：1998-07-01 00:00:00

abstract：:Nine individuals between 15 and 43 years of age with non-Hodgkin's lymphoma underwent allogeneic marrow transplantation following busulfan 16 mg/kg and cyclophosphamide 120 mg/kg. These individuals were not considered optimal candidates for autologous transplantation chiefly because of marrow involvement or resistance...

journal_title：Bone marrow transplantation

authors： Copelan EA,Kapoor N,Gibbins B,Tutschka PJ

更新日期：1990-01-01 00:00:00

abstract：:We investigated the serial changes in the blood CsA concentration during the switch from continuous intravenous infusion to twice-daily oral administration in allogeneic hematopoietic stem cell transplant recipients (n=12). The microemulsion form of CsA, Neoral, was started at twice the last dose in intravenous infusi...

journal_title：Bone marrow transplantation

authors： Kimura S,Oshima K,Okuda S,Sato K,Sato M,Terasako K,Nakasone H,Kako S,Yamazaki R,Tanaka Y,Tanihara A,Higuchi T,Nishida J,Kanda Y

更新日期：2010-06-01 00:00:00

abstract：:The impact of rhinovirus in hematopoietic SCT (HSCT) recipients is not well defined. A retrospective, matched, case-control study of HSCT recipients with rhinovirus was conducted between 2009 and 2011. Controls were matched for timing relative to transplant, malignancy, and stem cell source. There were 47 cases and 94...

journal_title：Bone marrow transplantation

authors： Abandeh FI,Lustberg M,Devine S,Elder P,Andritsos L,Martin SI

更新日期：2013-11-01 00:00:00

abstract：:Management of iatrogenic gonadal reproductive failure and sexual morbidity assumes a priority, especially in young recipients of high-dose chemotherapy and stem cell transplantation (SCT). Hormone replacement treatment (HRT) is beneficial for correction of sexual symptoms and osteoporosis in both sexes, especially in ...

journal_title：Bone marrow transplantation

authors： Chatterjee R,Kottaridis PD

更新日期：2002-11-01 00:00:00

abstract：:From May 1985 to July 1989, 76 patients with leukemia (30 acute myelogenous leukemia, 24 acute lymphoblastic leukemia and 22 chronic myeloid leukemia) were randomized to receive either cyclosporin (CSP) alone (n = 39) or CSP combined with methotrexate (CSP + MTX, n = 37) for graft-versus-host disease (GVHD) prophylaxi...

journal_title：Bone marrow transplantation

authors： Mrsić M,Labar B,Bogdanić V,Nemet D,Pavletić Z,Plavsić F,Dobrić I,Marusić M,Francetić I,Kastelan A

更新日期：1990-08-01 00:00:00

abstract：:The human recombinant G-CSF filgrastim has been widely used for the mobilization of CD34(+) stem cells of healthy donors (HD). In 2008, the G-CSF biosimilar XM02 (Ratiograstim, Tevagrastim and Biograstim) was approved by the European Medicines Agency (EMA) for the mobilization of PBSC. However, there is limited experi...

journal_title：Bone marrow transplantation

authors： Schmitt M,Xu X,Hilgendorf I,Schneider C,Borchert K,Gläser D,Freund M,Schmitt A

更新日期：2013-07-01 00:00:00

abstract：:One of the major aims of allogeneic haemopoietic stem cell transplantation has been the effective suppression of graft-versus-host disease (GVHD) without loss of a graft-versus-leukaemia effect. For GVHD suppression, one of the most frequently used regimens has been the combination of cyclosporin (CsA) and a short cou...

journal_title：Bone marrow transplantation

authors： Byrne JL,Stainer C,Hyde H,Miflin G,Haynes AP,Bessell EM,Russell NH

更新日期：1998-09-01 00:00:00

abstract：:The effectiveness of an antibody-enzyme immunotoxin (eIT) was investigated on human T cells. This enzyme immunotoxin contained glucose oxidase (GO) and lactoperoxidase (LPO) chemically coupled to the pan-leukocyte-specific mouse monoclonal antibody (MoAb) 097 (097-GO and 097-LPO). Human peripheral blood mononuclear ce...

journal_title：Bone marrow transplantation

authors： Ito HO,Morizet J,Coulombel L,Goavec M,Rousseau V,Bernard A,Stanislawski M

更新日期：1989-09-01 00:00:00

abstract：:Severe veno-occlusive disease (VOD), characterised by elevated serum bilirubin levels, is a known complication in the first 3 weeks after peripheral blood stem cell transplantation (PBSCT). Severe VOD is associated with capillary leakage and multiple organ dysfunction and leads to high mortality. We report a 17-year-o...

journal_title：Bone marrow transplantation

authors： Heying R,Nürnberger W,Spiekerkötter U,Göbel U

更新日期：1998-05-01 00:00:00

abstract：:In the United States the increasing number of Food and Drug Administration (FDA)-approved, innovative, and potentially effective commercial cancer therapies pose a significant financial burden on public and private payers. Chimeric antigen receptor (CAR) T cells are prototypical of this challenge. In 2017 and 2018, ti...

journal_title：Bone marrow transplantation

authors： Fiorenza S,Ritchie DS,Ramsey SD,Turtle CJ,Roth JA

更新日期：2020-09-01 00:00:00

abstract：:Cytomegalovirus (CMV) represents a major cause of morbidity after allogeneic stem cell transplantation (allo-SCT). Using interferon-gamma-enzyme-linked immunospot (ELISPOT) assay and HLA-peptide tetramers, we analysed 54 patients who received a reduced-intensity conditioning regimen, including fludarabine, busulphan a...

journal_title：Bone marrow transplantation

authors： Mohty M,Mohty AM,Blaise D,Faucher C,Bilger K,Isnardon D,Sainty D,Gastaut JA,Viens P,Olive D,Gaugler B

更新日期：2004-04-01 00:00:00

abstract：:Three patients developed abdominal pain and abnormal liver enzymes without hyperbilirubinemia, early after autografting for lymphoma. Two had received conditioning therapy with busulfan, cyclophosphamide and continuous infusion etoposide; the other had received busulfan and melphalan. Doppler ultrasound in all cases d...

journal_title：Bone marrow transplantation

authors： Grigg A,Gibson R,Bardy P,Szer J

更新日期：1996-11-01 00:00:00

abstract：:The management of acute leukaemia which relapses following an allogeneic stem cell transplant remains a major challenge. In this review we summarize the outcomes of the currently available treatment modalities and discuss emerging novel approaches. ...

journal_title：Bone marrow transplantation

authors： Shaw BE,Russell NH

更新日期：2008-03-01 00:00:00

abstract：:The bare lymphocyte syndrome is a combined immunodeficiency resulting from the lack of expression of either class I or class II HLA antigens at the cell surface. The main clinical manifestations are infections of the respiratory or the digestive tract. The immunodeficiency involves the absence of antibody formation an...

journal_title：Bone marrow transplantation

authors： Touraine JL,Marseglia GL,Betuel H,Souillet G,Gebuhrer L

更新日期：1992-01-01 00:00:00

abstract：:Invasive fungal infections are associated with significant morbidity and mortality among immunocompromised patients. Recent advances in antifungal development have afforded us more pharmacologic compounds to choose from when managing these fungal infections. The role of combination antifungal therapy has been well est...

journal_title：Bone marrow transplantation

authors： Johnson MD,Perfect JR

更新日期：2007-08-01 00:00:00

abstract：:The safety of injecting healthy donors with granulocyte colony-stimulating factor (G-CSF) has not been established. To evaluate PBSC mobilization and harvesting efficacy in the pediatric population, we compared it with those in adult donors. In this study, we conclude that PBSC mobilization and harvesting protocol in ...

journal_title：Bone marrow transplantation

authors： Kawano Y,Takaue Y,Watanabe T,Watanabe A,Iwai A,Kuroda Y

更新日期：1998-06-01 00:00:00

abstract：:The purpose of this work was to determine the maximum tolerated (phase II) dose of melphalan and etoposide that can be given in conjunction with autologous BM re-infusion in patients who have refractory or relapsed solid tumors. Twenty-six patients with refractory or relapsed breast cancer (n = 15), small cell lung ca...

journal_title：Bone marrow transplantation

authors： Lazarus HM,Gray R,Ciobanu N,Winter J,Weiner RS

更新日期：1994-09-01 00:00:00

abstract：:The immunostimulatory activity of viridans streptococcal strains isolated from neutropenic patients with severe sepsis (n=9) or uncomplicated bacteraemia (n=10) was compared. Peripheral blood mononuclear cells from healthy individuals were stimulated with heat-killed bacteria or culture supernatants, and cytokine prod...

journal_title：Bone marrow transplantation

authors： Ihendyane N,Sparrelid E,Wretlind B,Remberger M,Andersson J,Ljungman P,Ringdén O,Normark BH,Allen U,Low DE,Norrby-Teglund A

更新日期：2004-01-01 00:00:00

abstract：:Cord colitis syndrome (CCS) is a recently proposed clinical entity characterized by a persistent diarrheal illness after cord blood transplantation (CBT), which is not caused by GVHD or CMV colitis. CCS is histologically characterized by chronic active colitis with granulomatous inflammation and Paneth cell metaplasia...

journal_title：Bone marrow transplantation

authors： Shimoji S,Kato K,Eriguchi Y,Takenaka K,Iwasaki H,Miyamoto T,Oda Y,Akashi K,Teshima T

更新日期：2013-09-01 00:00:00

abstract：:This was an open-label, single-center, phase II study of 20 patients with multiple myeloma who were either proven poor mobilizers (n=10; group A) or predicted poor mobilizers (n=10; group B) and were planned for autologous hematopoietic SCT. The aim was to assess the safety and efficacy of plerixafor for stem cell mob...

journal_title：Bone marrow transplantation

authors： Tricot G,Cottler-Fox MH,Calandra G

更新日期：2010-01-01 00:00:00

abstract：:Donor-recipient sex incompatibility has been associated with transplant outcomes in allogeneic hematopoietic SCT. Such outcomes might be because mHA encoded by Y chromosome genes could be immunological targets for allogeneic T cells and B cells to induce GVHD, GVL effect and graft failure. However, its effect on the o...

journal_title：Bone marrow transplantation

authors： Konuma T,Kato S,Ooi J,Oiwa-Monna M,Ebihara Y,Mochizuki S,Yuji K,Ohno N,Kawamata T,Jo N,Yokoyama K,Uchimaru K,Tojo A,Takahashi S

更新日期：2014-05-01 00:00:00

abstract：:In a 34-year-old patient toxoplasma retinitis/encephalitis developed 9 months after bone marrow transplantation. The BMT was complicated with a serious GVHD. Although she initially responded well to antibiotic therapy she died 2 years after BMT due to progressive infection. ...

journal_title：Bone marrow transplantation

authors： Brinkman K,Debast S,Sauerwein R,Ooyman F,Hiel J,Raemaekers J

更新日期：1998-03-01 00:00:00

abstract：:Allogeneic hematopoietic cell transplantation (allo-HCT) for patients with AML is increasingly able to impact the historically poor outcomes in this disease. Nonetheless, even with transplant, the rates of post-HCT relapse are unacceptably high, and remain a great challenge in the treatment of patients with AML. Maint...

journal_title：Bone marrow transplantation

authors： Brunner AM,Fathi AT,Chen YB

更新日期：2016-11-01 00:00:00

abstract：:Veno-occlusive disease of the liver (VOD) is a common and severe complication of allogeneic hematopoietic stem cell transplantation (HSCT). To determine the incidence of, and the risk factors for the development of VOD, we performed a retrospective analysis of a series of 178 patients, who underwent allogeneic HSCT at...

journal_title：Bone marrow transplantation

authors： Moscardó F,Sanz GF,de La Rubia J,Jiménez C,Saavedra S,Regadera A,Andreu R,García I,Plumé G,Martínez J,Martín G,Jarque I,Sanz MA

更新日期：2001-05-01 00:00:00

abstract：:The severe phenotype of leukocyte adhesion deficiency is a rare, congenital disorder of leukocyte function that is usually fatal in the first few years of life. Allogeneic hematopoietic stem cell transplantation currently offers the only curative approach for this disease. We describe the first successful matched unre...

journal_title：Bone marrow transplantation

authors： Mancias C,Infante AJ,Kamani NR

更新日期：1999-12-01 00:00:00

abstract：:Clostridium difficile is the most common cause of nosocomial diarrhea in the United States and Europe, and is a cause of significant morbidity and mortality among hospitalized patients. A newly identified epidemic strain has been associated with many hospital outbreaks of C. difficile-associated disease (CDAD), raisin...

journal_title：Bone marrow transplantation

authors： Bobak D,Arfons LM,Creger RJ,Lazarus HM

更新日期：2008-12-01 00:00:00

abstract：:The incidence of varicella-zoster-virus infection/reactivation in adult patients with Hodgkin's disease undergoing autologous bone marrow transplantation (BMT) at the University of Minnesota Hospital and Clinic was determined. Seven of 28 evaluable patients (25%) developed varicella-zoster infections in the first 150 ...

journal_title：Bone marrow transplantation

authors： Christiansen NP,Haake RJ,Hurd DD

更新日期：1991-06-01 00:00:00

abstract：:The clonality pattern of immunoglobulins (Igs) produced after allogeneic bone marrow transplantation (BMT) was studied by high-resolution two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) of serum samples and purified Igs. With this technique, the light (L) chain of a monoclonal Ig usually appears as a sing...

journal_title：Bone marrow transplantation

authors： Tissot JD,Helg C,Chapuis B,Zubler RH,Jeannet M,Hochstrasser DF,Hohlfeld P,Schneider P

更新日期：1992-10-01 00:00:00